A highly motivated and innovative biologist with extensive management and leadership experience and proven track record in drug discovery and development. Comprehensive knowledge in oncology, immunology and metabolism. Broad expertise in target validation, translational research and biomarker discovery. Skilled in strategic planning and execution in alignment with corporate goals and objectives. Experienced with business development and partnership due diligence. Demonstrated ability in building and leading high-performing cross-functional teams. Proven publication and patent record.
Zhigang Weng is a highly motivated and innovative biologist with 25.8 years of experience in drug discovery and development. He has extensive knowledge in oncology, immunology, and metabolism, and is skilled in target validation, translational research, and biomarker discovery. Zhigang has a proven track record in strategic planning and execution, and has successfully led cross-functional teams. He has held various leadership positions in renowned companies such as Curie Therapeutics, Blueprint Medicines, and Forma Therapeutics. Zhigang is based in the United States.
Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines directly to patients in the United States and Europe, and we are advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. With patients at the center of our mission, we aim to make real the promise of precision medicine to improve and extend life for as many people with cancer and blood disorders as possible. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity, and diversity pushes us to lead with integrity, act courageously, and draw upon a wide range of backgrounds and perspectives to make decisions. Ideas come from everywhere, from the C-suite to new hires, and each day we commit to approach one another with respect and trust. We care deeply about making a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
Forma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. We aim to create futures for patients, their families and our employees. Learn more about our mission, discover our “Whole You” benefits package and search for your next career opportunity: https://www.formatherapeutics.com/careers/ Read our community guidelines: https://www.formatherapeutics.com/community-guidelines/
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. For the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.
We are relentlessly pursuing excellence – daring to believe that a cure can be a reality. Infinity Pharmaceuticals, Inc., is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies, Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
High Throughput Screening
We found 3 Zhigang Weng's email addresses
We found 1 Zhigang Weng's phone numbers
Zhigang Weng's social media include: Linkedin,
Zhigang Weng works for Curie Therapeutics
Zhigang Weng's role in Curie Therapeutics is Vice President Head Of Biology
Zhigang Weng works in the industry of
Zhigang Weng's latest job experience is Vice President Head Of Biology at Curie Therapeutics
Zhigang Weng's latest education in University of Pennsylvania School of Medicine